Shares of Hester Biosciences Ltd rallied 14 per cent to Rs 3,099 on the BSE in the intra-day trade on Friday, surging 22 per cent in two days, after the company said it is part of a MoU between vaccine maker Bharat Biotech and Gujarat Covid Vaccine Consortium (GCVC) for contract manufacturing the drug substance for Covaxin.
The company said a memorandum of understanding (MoU) has been signed between Bharat Biotech (BB) International Limited and Gujarat Covid Vaccine Consortium (GCVC) towards contract manufacturing for the drug substance for COVAXIN, of which Hester is a part.
GCVC comprises of Gujarat Biotechnology Research Centre (GBRC), a Government of Gujarat undertaking, Hester Biosciences, and Omnibrx Biotechnologies Private Limited.
“”BB shall provide the technology for the production of the drug substance for COVAXIN. GBRC will act as an advisor and mentor and will facilitate the technology transfer from Bharat Biotech. Hester shall provide the complete infrastructure at its Gujarat plant for the manufacturing of the drug substance and Omnibrx shall act as a technology support partner,” Hester Biosciences said in a statement. This entire process is facilitated by the Department of Biotechnology, Government of India, it added.
- Minda Corporation Shares Rally 5% on Plans to Acquire Stake in Flash Electronics
- Stocks Under F&O Ban: Hindustan Copper, RBL Bank, and Others
- Stocks in Focus: J&K Bank, IRFC, Adani Green Energy, Vodafone Idea, and Others
- Govt plans new route connecting Noida airport to NH-34
- India Ranks Third in Global Fintech Funding, Despite 33% Drop in 2024
The technology transfer from BB will enable Hester to provide the drug substance from August 2021 to BB for its vaccine production. The company has estimated an outlay of Rs 40 crore for this project.
Stock Covered in the news
